Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion Inhibitor: A promising strategy for discovering new antiviral therapeutics

Journal of Medicinal Chemistry

Volumn 57, Issue 17, 2014, Pages 7342-7354

  Wang, Chao ^a   Lu, Lu ^b   Na, Heya ^a   Li, Xiangpeng ^a   Wang, Qian ^b   Jiang, Xifeng ^a   Xu, Xiaoyu ^a   Yu, Fei ^c   Zhang, Tianhong ^a   Li, Jinglai ^a   Zhang, Zhenqing ^a   Zheng, Baohua ^a   Liang, Guodong ^a   Cai, Lifeng ^a   Jiang, Shibo ^b,c   Liu, Keliang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA(PENT 4' YNOYLOXY)LUP 20(29) EN 28 OIC ACID; 3BETA(PENT 4' YNOYLOXY)OLEAN 12 EN 28 OIC ACID; 3BETA(PENT 4' YNOYLOXY)URS 12 EN 28 OIC ACID; ALLYL 3BETA(PENT 4' YNOYLOXY)LUP 20(29) EN 28 OATE; ALLYL 3BETA(PENT 4' YNOYLOXY)OLEAN 12 EN 28 OATE; ALLYL 3BETA(PENT 4' YNOYLOXY)URS 12 EN 28 OATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENFUVIRTIDE; PROP 2' YNYL 3BETA ACETOXYLUP 20(29) EN 28 OATE; PROP 2' YNYL 3BETA HYDROXYLUP 20(29) EN 28 OATE; PROP 2' YNYL 3BETA HYDROXYOLEAN 12 EN 28 OATE; PROP 2' YNYL 3BETA HYDROXYURS 12 EN 28 OATE; SAPOGENIN; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTIVIRUS AGENT; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ACYLATION; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CELL MEMBRANE; CLICK CHEMISTRY; COMPETITIVE INHIBITION; COVALENT BOND; CYCLOADDITION; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DESIGN; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN BA L); HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN IIIB); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; IN VITRO STUDY; IN VIVO STUDY; LIPID BILAYER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PALMITOYLATION; RAT; SINGLE DRUG DOSE; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS REPLICATION; VIRUS STRAIN; AMINO ACID SEQUENCE; CELL LINE; CELL SURVIVAL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; SAPOGENINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907225755     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500763m     Document Type: Article

References (54)

1. Pan, C.; Liu, S.; Jiang, S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics J. Formosan Med. Assoc. 2010, 109 (2) 94-105
2. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41 ChemMedChem 2010, 5 (11) 1813-1824
3. Harrison, S. C. Viral membrane fusion Nature Struct. Mol. Biol. 2008, 15, 690-698
4. Naider, F.; Anglister, J. Peptides in the treatment of AIDS Curr. Opin. Struct. Biol. 2009, 19 (4) 473-482
5. Porotto, M.; Yokoyama, C. C.; Palermo, L. M.; Mungall, B.; Aljofan, M.; Cortese, R.; Pessi, A.; Moscona, A. Viral entry inhibitors targeted to the membrane site of action J. Virol. 2010, 84 (13) 6760-6768
6. Berkhout, B.; Eggink, D.; Sanders, R. W. Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2012, 2, 50-59
7. Naito, T.; Izumi, K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos, S. G.; Oishi, S.; Fujii, N.; Matsuoka, M. SC29EK, a peptide fusion inhibitor with enhanced α-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide Antimicrob. Agents Chemother. 2009, 53 (3) 1013-1018
8. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273
9. Chan, D. C.; Kim, P. S. HIV entry and its inhibition Cell 1998, 93, 681-684
10. Gallo, S. A.; Puri, A.; Blumenthal, R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process Biochemistry (Moscow) 2001, 40, 12231-12236
11. Ashkenazi, A.; Shai, Y. Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides Eur. Biophys. J. 2011, 40 (4) 349-357
12. Shi, W.; Cai, L.; Lu, L.; Wang, C.; Wang, K.; Xu, L.; Zhang, S.; Han, H.; Jiang, X.; Zheng, B.; Jiang, S.; Liu, K. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences Chem. Commun. 2012, 48, 11579-11581
13. Jiang, S.; Zhao, Q.; Debnath, A. K. Peptide and non-peptide HIV fusion inhibitors Curr. Pharm. Des. 2002, 8, 563-580
14. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 9770-9774
15. Ferrer, M.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Wiley, D. C.; Harrison, S. C. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements Nature Struct. Biol. 1999, 6 (10) 953-960
16. Qi, Z.; Shi, W.; Xue, N.; Pan, C.; Jing, W.; Liu, K.; Jiang, S. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors J. Biol. Chem. 2008, 283 (44) 30376-30384
17. Liu, S.; Jing, W.; Cheung, B.; Lu, H.; Sun, J.; Yan, X.; Niu, J.; Farmar, J.; Wu, S.; Jiang, S. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisims of action of anti-HIV peptides J. Biol. Chem. 2007, 282 (13) 9612-9620
18. Münch, J.; Ständker, L.; Adermann, K.; Schulz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; Meyer, B.; Wilhelm, D.; Lu, H.; Jing, W. G.; Jiang, S. B.; Forssmann, W. G.; Frank, K. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide Cell 2007, 129, 263-275
19. Forssmann, W. G.; The, Y. H.; Stoll, M.; Adermann, K.; Albrecht, U.; Tillmann, H. C.; Barlos, K.; Busmann, A.; Canales-Mayordomo, A.; Giménez-Gallego, G.; Hirsch, J.; Jiménez-Barbero, J.; Meyer-Olson, D.; Münch, J.; Pérez-Castells, J.; Ständker, L.; Kirchhoff, F.; Schmidt, R. E. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide Sci. Transl. Med. 2010, 2, 63re3
20. Herrera, E.; Tenckhoff, S.; Gómara, M. J.; Galatola, R.; Bleda, M. J.; Gil, C.; Ercilla, G.; Gatell, J. M.; Tillmann, H. L.; Haro, I. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection J. Med. Chem. 2010, 53, 6054-6063
21. Osbourn, A.; Gossb, R. J. M.; Field, R. A. The saponins: polar isoprenoids with important and diverse biological activities Nat. Prod. Rep. 2011, 28, 1261-1268
22. Yu, D.; Sakurai, Y.; Chen, C. H.; Chang, F. R.; Huang, L.; Kashiwada, Y.; Lee, K. H. Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents J. Med. Chem. 2006, 49, 5462-5469
23. Rattanathongkom, A.; Lee, J. B.; Hayashi, K.; Sripanidkulchai, B. O.; Kanchanapoom, T.; Hayashi, T. Planta Med. 2009, 75, 829-835
24. Augustin, J. M.; Kuzina, V.; Andersen, S. B.; Bak, S. Molecular activities, biosynthesis and evolution of triterpenoid saponins Phytochemistry 2011, 72, 435-457
25. Sun, H. X.; Chen, L. Q.; Wang, J. J.; Wang, K. W.; Zhou, J. Y. Structure-function relationship of the saponins from the roots of Platycodon grandiflorum for hemolytic and adjuvant activity Int. Immunopharmacol. 2011, 11, 2047-2056
26. Ding, N.; Chen, Q.; Zhang, W.; Ren, S. M.; Guo, Y.; Li, Y. X. Structure-activity relationships of saponin derivatives: a series of entry inhibitors for highly pathogenic H5N1 influenza virus Eur. J. Med. Chem. 2012, 53, 316-326
27. Eckert, D. M.; Kim, P. S. Mechanism of viral membrane fusion and its inhibition Annu. Rev. Biochem. 2001, 70, 777-810
28. Shi, W.; Qi, Z.; Pan, C.; Xue, N.; Debnath, A. K.; Qie, J.; Jiang, S.; Liu, K. Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs Biochem. Biophys. Res. Commun. 2008, 374, 767-772
29. Wang, C.; Shi, W.; Cai, L.; Lu, L.; Wang, Q.; Zhang, T.; Li, J.; Zhang, Z.; Wang, K.; Xu, L.; Jiang, X.; Jiang, S.; Liu, K. Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors J. Med. Chem. 2013, 56 (6) 2527-2539
30. Kashiwada, Y.; Hashimoto, F.; Cosentino, L. M.; Chen, C. H.; Garrett, P. E.; Lee, K. H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents J. Med. Chem. 1996, 39, 1016-1017
31. Fujioka, T.; Kashiwada, Y.; Kilkuskie, R. E.; Cosentino, L. M.; Ballas, L. M.; Jiang, J. B.; Janzen, W. P.; Chen, I. S.; Lee, K. H. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids J. Nat. Prod. 1994, 57, 243-247
32. Qian, K.; Bori, I. D.; Chen, C. H.; Huang, L.; Lee, K. H. Anti-AIDS agents 90. Novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors J. Med. Chem. 2012, 55, 8128-8136
33. Dang, Z.; Ho, P.; Zhu, L.; Qian, K.; Lee, K. H.; Huang, L.; Chen, C. H. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1 J. Med. Chem. 2012, 56, 2029
34. Aiken, C.; Chen, C. H. Betulinic acid derivatives as HIV-1 antivirals Trends Mol. Med. 2005, 11, 31-36
35. Qian, K.; Kuo, R.; Chen, C. H.; Huang, L.; Morris-Natschke, S. L.; Lee, K. H. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors J. Med. Chem. 2010, 53, 3133-3141
36. Dang, Z.; Qian, K.; Ho, P.; Zhu, L.; Lee, K. H.; Huang, L.; Chen, C. H. Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants Bioorg. Med. Chem. Lett. 2012, 22, 5190-5194
37. Yu, D. L.; Sakurai, Y.; Chen, C. H.; Chang, F. R.; Huang, L.; Kashiwada, Y.; Lee, K. H. Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents J. Med. Chem. 2006, 49, 5462-5469
38. Savina, A. A.; Fesenko, D. A.; Sheichenko, V. I.; Shavlinskii, A. N. Nature of the transformations of oleanolic acid in an acid medium Chem. Nat. Compd. 1986, 22 (3) 295-297
39. Hein, J. E.; Fokin, V. V. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides Chem. Soc. Rev. 2010, 39, 1302-1315
40. Hong, V.; Presolski, S. I.; Ma, C.; Finn, M. G. Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation Angew. Chem. Int, Ed. 2009, 48, 9879-9883
41. Guptasarma, P.; Balasubramanian, D. Hydroxyl radical mediated damage to proteins, with special reference to the crystallins Biochemistry 1992, 31, 4296-4303
42. Lu, L.; Tong, P.; Yu, X.; Pan, C.; Zou, P.; Chen, Y.; Jiang, S. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain Biochim. Biophys. Acta, Biomembr. 2012, 1818 (12) 2950-2957
43. Harada, S.; Yokomizo, K.; Monde, K.; Maeda, Y.; Yusa, K. A broad antiviral neutral glycolipid, fattiviracin FV-8, is a membrane fluidity modulator Cell. Microbiol. 2007, 9, 196-203
44. Harada, S. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope Biochem. J. 2005, 392, 191-199
45. Ashkenazi, A.; Viard, M.; Unger, L.; Blumenthal, R.; Shai, Y. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1 FASEB J. 2012, 26, 4628-4636
46. Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T. J.; Moore, J. P.; Miller, M. D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (14) 5801-5806
47. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds Curr. Pharm. Des. 2007, 13 (2) 143-162
48. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The future of peptide-based drugs Chem. Biol. Drug Des. 2013, 81, 136-147
49. Gupta, S.; Jain, A.; Chakraborty, M.; Sahni, J. K.; Ali, J.; Dang, S. Oral delivery of therapeutic proteins and peptides: a review on recent developments Drug Delivery 2013, 20, 237-246
50. Renukuntla, J.; Vadlapudi, A. D.; Patel, A.; Boddu, S. H. S.; Mitra, A. K. Approaches for enhancing oral bioavailability of peptides and proteins Int. J. Pharm. 2013, 447, 75-93
51. Wexler-Cohen, Y.; Shai, Y. Demonstrating the C-terminal boundary of the HIV-1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition FASEB J. 2007, 21 (13) 3677-3684
52. Lu, L.; Pan, C.; Li, Y.; Lu, H.; Wu, H.; Jiang, S. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains Retrovirology 2012, 9, 104
53. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 2006, 58, 621-681
54. Tong, P.; Lu, Z.; Chen, X.; Wang, Q.; Yu, F.; Zou, P.; Yu, X.; Li, Y.; Lu, L.; Chen, Y. H.; Jiang, S. B. An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides J. Antimicrob. Chemother. 2013, 68, 2533-2544